Drug intelligence / Profile preview

physostigmine + scopolamine

Development stage: Preclinical
Lead developer: UK Armed Forces
Modality: Small Molecules
Administration: Subcutaneous

Overview

A combination of physostigmine and scopolamine that has been studied primarily as a protective treatment against nerve agent toxicity. Physostigmine is a cholinesterase inhibitor that crosses the blood-brain barrier, while scopolamine is an anticholinergic agent. This combination has demonstrated protection against the lethal and behavioral effects of nerve agents such as soman and sarin.

Targets

mAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine ReceptorAcetylcholinesterase

Beyond the preview

Go deeper on physostigmine + scopolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on physostigmine + scopolamine.

Explore the full profile